evodiamine has been researched along with Experimental Lung Inflammation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, B; Huang, W; Li, X; Peng, C; Xie, X; Ye, C; Zhang, N; Zhao, Q; Zhu, HP | 1 |
| Chen, X; Li, H; Zhou, S | 1 |
2 other study(ies) available for evodiamine and Experimental Lung Inflammation
| Article | Year |
|---|---|
Evodiamine alleviates lipopolysaccharide-induced pulmonary inflammation and fibrosis by activating apelin pathway.
Topics: Animals; Apelin; Apoptosis; Cytokines; Evodia; Fibrosis; Humans; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Plant Extracts; Pneumonia; Quinazolines; RAW 264.7 Cells | 2021 |
Evodiamine alleviates severe pneumonia induced by methicillin-susceptible Staphylococcus aureus following cytomegalovirus reactivation through suppressing NF-ÎșB and MAPKs.
Topics: Animals; Blotting, Western; Cell Line; Cytomegalovirus; Female; Humans; Interleukin-1beta; Interleukin-6; Methicillin; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinases; NF-kappa B; Pneumonia; Quinazolines; Signal Transduction; Staphylococcus aureus; Tumor Necrosis Factor-alpha | 2018 |